Articles

Pharma industry awaits impact of Obama’s second term

Now that the American people have spoken—with about 120 million votes estimated to have been cast as we went to press with this issue—and reelected President Barack Obama to a second term, many of you may be asking, “How will this affect pharma?”
Written byAmy Swinderman
| 4 min read

Now that the American people have spoken—with about 120million votes estimated to have been cast as we went to press with this issue—andreelected President Barack Obama to a second term, many of you may be asking,"How will this affect pharma?"

It's a heavy question, given how the passage of the PatientProtection and Affordable Care Act (PPACA) during the president's first termalready has the pharma and biotech industries busy assessing how to do businessin a new healthcare paradigm. But with many facets of the new law taking effectas the president's second term begins, tongues are wagging, and all eyes are onthe phasing in of some of the particulars of the 2,000-plus-page bill.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D molecular visualization of a protein structure, rendered in a ribbon diagram style.
A comparative structural analysis of MC4R complexes reveals how agonist binding influences receptor conformation, ligand interactions, and complex stability.
Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.